The FDA Complete Response Letter: what it is and what happens next

A Complete Response Letter (CRL) is the FDA's way of telling a sponsor, at the end of a review cycle, that it has finished evaluating a marketing application and will not approve it in its present form. It is not a rejection in the colloquial sense and it does not end the application. It is a formal action letter that closes one review cycle, catalogs every deficiency the review division identified, and hands the sponsor a defined set of next steps under the regulations. For a regulatory affairs team, the CRL is the document that resets the clock and defines the remediation agenda.

What the letter actually says

CRLs are built on standardized boilerplate. The opening paragraph reads, in substance: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues." ⁹²⁹³⁹⁵ That single sentence carries the three points that define the action: the review cycle is complete, the application is not approvable as submitted, and the reasons (the deficiencies) follow in the body of the letter. ⁹²⁹³⁹⁵

The body then lists deficiencies by topic, which can include clinical efficacy, safety and benefit-risk, chemistry/manufacturing/controls (CMC), facility inspections, labeling, proprietary name, and a required safety update. ⁶⁷⁶⁸⁹² A CRL almost always addresses more than one review discipline, so the remediation work is rarely confined to a single function.

The sponsor's options after receiving a CRL

The letter itself tells the sponsor what it must do. The standard language for an NDA is: "Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110." ¹¹¹¹¹³¹¹⁵ For a BLA, the same structure points to 21 CFR 601.3(b). ¹¹²¹¹⁴¹¹⁶ In practice the "other actions available" resolve into three paths: resubmit the application with a response to the deficiencies, withdraw the application, or pursue the other procedural options the regulation allows.

Two consequences are spelled out directly in the letter:

Deemed withdrawal for inaction. "If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65." ¹¹¹¹¹³¹¹⁵ For BLAs the parallel citation is 21 CFR 601.3(c). ¹¹²¹¹⁴¹¹⁶ The one-year window is therefore not advisory; letting it lapse without action can be treated as a request to withdraw.
Extensions are available. "You may also request an extension of time in which to resubmit the application." ¹¹¹¹¹³¹¹⁵ Sponsors that need more than a year to generate data or complete manufacturing remediation can ask for additional time rather than defaulting to withdrawal.

A practical caveat from the source letters: the standard CRL text describes the resubmit / take-other-action / one-year / deemed-withdrawal framework, but the letters generally do not enumerate every option under 314.110 (such as an explicit request for a hearing) in their own text. ¹¹¹¹¹³ The full menu of options lives in the regulation the letter cross-references.

What a resubmission has to do

FDA treats the resubmission, not further correspondence, as the event that starts a new review cycle. The letters are explicit: "A resubmission must fully address all the deficiencies listed," and "A partial response to this letter will not be processed as a resubmission and will not start a new review cycle." ⁶⁰ A resubmission is also marked "RESUBMISSION" and must be a complete response to every deficiency, not a subset. ¹⁶¹¹⁶² In at least one case, FDA noted that answers to specific information requests could be sent as a separate amendment, but the resubmission still had to fully resolve the CRL deficiencies. ⁶⁰

On how the resubmission is reviewed once received, the letters say relatively little and vary. Most simply restate the one-year and full-response requirements. ¹⁶¹¹⁶²¹³⁰ A few speak to review handling directly: FDA told Adamis Pharmaceuticals (NDA 212854) that "resubmission goals will not apply to any resubmission of this application." ¹⁸² Other letters (for example, Heritage/Avet NDA 205508 and Tris Pharma NDA 220138) require action within one year and allow an extension but state no post-receipt review goal date. ¹²²¹³⁰ Sponsors should not assume a specific resubmission review timeline from the CRL text alone; it depends on how the resubmission is classified when it is filed.

Engaging FDA after the letter

CRLs invite dialogue. The standard closing language is: "You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products." ¹⁶²¹³²¹³⁴ For most sponsors, requesting a post-action meeting is the first substantive step after a CRL: it is the forum to confirm what FDA will accept as an adequate response, align on any new studies, and reduce the risk of a second-cycle failure.

The deficiency categories, with real examples

What lands in a CRL is best understood through the review disciplines FDA actually cites.

Clinical efficacy

The most consequential CRLs are those requiring new evidence of effectiveness, because they typically add years to a program:

Troriluzole for spinocerebellar ataxia (Biohaven, NDA 210862): the randomized study failed all primary and secondary endpoints; post hoc subgroup and fall analyses were not persuasive, and FDA said an adequate and well-controlled study on a clinically meaningful endpoint would be needed. ¹
Vatiquinone for Friedreich's ataxia (PTC Therapeutics, NDA 220049): MOVE-FA failed its prespecified primary and key secondary endpoints; the exploratory result was not robust to missing-data and baseline-imbalance issues. ⁹
Depemokimab for CRSwNP (GSK, BLA 761458): co-primary endpoints were statistically significant, but nasal obstruction scores were not robust to sensitivity analyses and effect sizes were small, so FDA asked for new evidence of a treatment effect of sufficient magnitude. ¹⁸
Glepaglutide for short bowel syndrome (Zealand Pharma, NDA 218828): efficacy endpoints were sensitive to body-weight loss with inconsistent results, and FDA recommended a second adequate and well-controlled trial. ⁶⁸
Govorestat for classic galactosemia (Applied Therapeutics, NDA 219195): major data-quality problems undermined reliance on the efficacy data, and the trial also failed its prespecified primary endpoints. ¹⁵

Safety and benefit-risk (including REMS)

Safety CRLs turn on whether the benefit-risk balance is acceptable and whether risk can be managed:

Jatenzo (oral testosterone undecanoate, Clarus, NDA 206089): FDA found the benefit-risk profile unfavorable because of clinically meaningful blood pressure increases and cardiovascular risk, and asked for labeling strategies and a REMS with elements to assure safe use. ²⁶⁵
A buprenorphine/naloxone film (Teva): FDA required a REMS given risks of misuse, abuse, and accidental overdose, plus a safety update covering all nonclinical and clinical data. ²⁵⁰
Ablysinol: FDA required a patient registry to capture peri- and post-procedural adverse events because limited safety data could not reliably estimate serious cardiac risks. ²⁵⁴
Postmarketing safety commitments also appear as conditions tied to resolving a CRL, for example a pregnancy safety study for apitegromab ²⁵⁹ and pregnancy/lactation studies for cytisinicline. ²⁶¹

CMC and facility inspections

A very common reason applications stall is that manufacturing is not ready, independent of the clinical data. These letters frequently state that a satisfactory inspection is required before approval:

scPharmaceuticals (Furoscix, NDA 209988): deficiencies at the manufacturing facility had to be resolved, and a required inspection of a Sharp facility could not be completed due to travel restrictions; FDA said the application could not be approved until the inspection was conducted and assessed, even if all other issues were resolved. ⁶⁵
MediWound (BLA 761192): required inspections of drug substance and drug product facilities were not completed, and FDA said the application could not be approved until they were. ⁶⁶
NorthStar Medical Radioisotopes (NDA 202158): a referenced DMF was deficient and facilities were not ready for inspection. ⁶⁸
Detailed CMC gaps also block approval on their own, for example missing method validation for in-process bioburden testing, incomplete process validation, and elemental impurity controls across letters to MediWound ⁷⁰, Astellas (NDA 209529) ⁷², and InnoPharma (NDA 206968). ⁷⁵

Labeling and proprietary name

Labeling and naming deficiencies rarely sink an application by themselves, but they must be cleared before approval:

Carton and container labeling fixes are routine, for example Trevena's OLINVYK (NDA 210730) requiring distinct NDC codes and affirmative warning language ²²⁶, and Camargo's Mycapssa requiring "delayed-release" in the product name. ²³²
Proprietary names are typically handled as "acceptable pending approval" or "conditionally acceptable pending approval," as with Semglee ²²¹, Zimhi ²²², OLINVYK ²²⁶, and Kisunla. ²⁴¹
A name review can also be terminated because of application deficiencies, as FDA did for Ipsen's proposed name in BLA 761311. ²²⁹

How to read a CRL as a regulatory reviewer

Three things matter most when a CRL arrives. First, sort the deficiencies by remediation horizon: a labeling or facility-inspection item may be resolvable in one cycle, while a request for a new adequate and well-controlled trial is a multi-year commitment. The Biohaven ¹ and PTC ⁹ letters sit at the expensive end; many CMC and labeling items do not. Second, protect the one-year clock: resubmit, request an extension, or take another action, because inaction can be treated as a withdrawal request. ¹¹¹¹¹³ Third, use the post-action meeting to convert FDA's written deficiencies into an agreed, testable response before spending on the resubmission, since a partial response does not start a new cycle. ⁶⁰¹⁶²

A CRL is best understood not as a verdict but as a scope-of-work document. It tells the sponsor exactly what FDA needs, on what regulatory timeline, and through what procedural path, and the quality of the response, not the fact of the letter, determines whether the next cycle ends in approval.

The FDA Complete Response Letter: What It Is and What Happens Next